Perspectives in post-transplantation immunotherapy in breast cancer

N. McCarthy, Claude Sportes, R. E. Gress

Research output: Contribution to journalArticle

Abstract

High risk and metastatic breast cancer remain a major therapeutic challenge. Although the role of high dose chemotherapy followed by stem cell transplantation (SCT) in the overall treatment strategy is not yet well defined, it is clear that new forms of therapy such as immunotherapy will be needed to cure the majority of patients with advanced disease. We review important considerations for immunotherapy in the post-transplantation period. Experimental and clinical data suggest that immunotherapy may be most effective in a state of minimal residual disease such as that achieved following SCT. However, high dose therapy and autologous SCT result in an iatrogenic immune deficiency, which compounds the suppression of the immune system associated with tumor itself. Understanding reconstitution of a functional immune system post transplantation is critical in devising clinically effective immune interventions. A review of the clinical studies of post transplant immunotherapy for breast cancer is presented including autologous and allogeneic strategies, as well as perspectives for future development.

Original languageEnglish (US)
Pages (from-to)69-79
Number of pages11
JournalBreast Disease
Volume14
DOIs
StatePublished - Jan 1 2001

Fingerprint

Immunotherapy
Stem Cell Transplantation
Transplantation
Breast Neoplasms
Immune System
Residual Neoplasm
Therapeutics
Transplants
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Perspectives in post-transplantation immunotherapy in breast cancer. / McCarthy, N.; Sportes, Claude; Gress, R. E.

In: Breast Disease, Vol. 14, 01.01.2001, p. 69-79.

Research output: Contribution to journalArticle

McCarthy, N. ; Sportes, Claude ; Gress, R. E. / Perspectives in post-transplantation immunotherapy in breast cancer. In: Breast Disease. 2001 ; Vol. 14. pp. 69-79.
@article{2f5f7075493e463a9c9601aa85813b8f,
title = "Perspectives in post-transplantation immunotherapy in breast cancer",
abstract = "High risk and metastatic breast cancer remain a major therapeutic challenge. Although the role of high dose chemotherapy followed by stem cell transplantation (SCT) in the overall treatment strategy is not yet well defined, it is clear that new forms of therapy such as immunotherapy will be needed to cure the majority of patients with advanced disease. We review important considerations for immunotherapy in the post-transplantation period. Experimental and clinical data suggest that immunotherapy may be most effective in a state of minimal residual disease such as that achieved following SCT. However, high dose therapy and autologous SCT result in an iatrogenic immune deficiency, which compounds the suppression of the immune system associated with tumor itself. Understanding reconstitution of a functional immune system post transplantation is critical in devising clinically effective immune interventions. A review of the clinical studies of post transplant immunotherapy for breast cancer is presented including autologous and allogeneic strategies, as well as perspectives for future development.",
author = "N. McCarthy and Claude Sportes and Gress, {R. E.}",
year = "2001",
month = "1",
day = "1",
doi = "10.3233/BD-2001-14108",
language = "English (US)",
volume = "14",
pages = "69--79",
journal = "Breast Disease",
issn = "0888-6008",
publisher = "IOS Press",

}

TY - JOUR

T1 - Perspectives in post-transplantation immunotherapy in breast cancer

AU - McCarthy, N.

AU - Sportes, Claude

AU - Gress, R. E.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - High risk and metastatic breast cancer remain a major therapeutic challenge. Although the role of high dose chemotherapy followed by stem cell transplantation (SCT) in the overall treatment strategy is not yet well defined, it is clear that new forms of therapy such as immunotherapy will be needed to cure the majority of patients with advanced disease. We review important considerations for immunotherapy in the post-transplantation period. Experimental and clinical data suggest that immunotherapy may be most effective in a state of minimal residual disease such as that achieved following SCT. However, high dose therapy and autologous SCT result in an iatrogenic immune deficiency, which compounds the suppression of the immune system associated with tumor itself. Understanding reconstitution of a functional immune system post transplantation is critical in devising clinically effective immune interventions. A review of the clinical studies of post transplant immunotherapy for breast cancer is presented including autologous and allogeneic strategies, as well as perspectives for future development.

AB - High risk and metastatic breast cancer remain a major therapeutic challenge. Although the role of high dose chemotherapy followed by stem cell transplantation (SCT) in the overall treatment strategy is not yet well defined, it is clear that new forms of therapy such as immunotherapy will be needed to cure the majority of patients with advanced disease. We review important considerations for immunotherapy in the post-transplantation period. Experimental and clinical data suggest that immunotherapy may be most effective in a state of minimal residual disease such as that achieved following SCT. However, high dose therapy and autologous SCT result in an iatrogenic immune deficiency, which compounds the suppression of the immune system associated with tumor itself. Understanding reconstitution of a functional immune system post transplantation is critical in devising clinically effective immune interventions. A review of the clinical studies of post transplant immunotherapy for breast cancer is presented including autologous and allogeneic strategies, as well as perspectives for future development.

UR - http://www.scopus.com/inward/record.url?scp=0035669936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035669936&partnerID=8YFLogxK

U2 - 10.3233/BD-2001-14108

DO - 10.3233/BD-2001-14108

M3 - Article

C2 - 15687637

AN - SCOPUS:0035669936

VL - 14

SP - 69

EP - 79

JO - Breast Disease

JF - Breast Disease

SN - 0888-6008

ER -